Follow this preprint

Cost-effectiveness of CTC guided chemo- or endocrine therapy in ER+ HER2- metastatic breast cancer – results from a randomized controlled multicenter trial

A.M.S. Berghuis, H. Koffijberg, X.G.L.V. Pouwels, F. Berger, C. Alix-Panabières, W. Jacot, J.Y. Pierga, F.C. Bidard, M.J. IJzerman
doi: https://doi.org/10.1101/2023.10.09.23296711
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Back to top
Posted October 09, 2023.
Download PDF
Print/Save Options
Download PDFFull Text & In-line FiguresXML

Supplementary Material

Data/Code
Email
Cost-effectiveness of CTC guided chemo- or endocrine therapy in ER+ HER2- metastatic breast cancer – results from a randomized controlled multicenter trial
A.M.S. Berghuis, H. Koffijberg, X.G.L.V. Pouwels, F. Berger, C. Alix-Panabières, W. Jacot, J.Y. Pierga, F.C. Bidard, M.J. IJzerman
medRxiv 2023.10.09.23296711; doi: https://doi.org/10.1101/2023.10.09.23296711
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area

Reviews and Context

0

Comment

0

TRIP Peer Reviews

0

Community Reviews

0

Automated Services

0

Blogs/Media

0

Author Videos

You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the preprints you are currently following, please go to the medRxiv Alerts Page.

Sign In to Follow this Preprint

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.